Eikon Therapeutics, Inc. Common Stock (EIKN) Stock

Eikon Therapeutics, Inc. Common Stock (EIKN) is a Healthcare stock trading at $10.74 (as of 2026-08-20), with a market capitalization of $582.00M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Eikon Therapeutics, Inc. is a U.S. clinical biopharmaceutical company developing therapies and a technology platform focused on characterizing protein interactions in living cells. Its pipeline includes TLR7/8 and PARP1 inhibitor programs, as well as agents targeting WRN helicase, intended for cancer indications across multiple tumor types.

Valuation — source: SEC EDGAR (first-party)
Price$10.74
Market Cap$582.00M
Price / Book1.25
FCF Yield-80.2%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($40.59M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEORoger Perlmutter
CountryUS
IPO Date2026-02-05

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • 4D Molecular Therapeutics, Inc. (FDMT)
  • Allogene Therapeutics, Inc. (ALLO)
  • Tectonic Therapeutic, Inc. (TECX)
  • Prime Medicine, Inc. (PRME)
  • REGENXBIO Inc. (RGNX)
  • Zura Bio Limited (ZURA)
  • Artiva Biotherapeutics, Inc. (ARTV)
  • C4 Therapeutics, Inc. (CCCC)
EIKN earnings history · EIKN institutional & insider holders · EIKN KPIs & operating metrics · EIKN financials · EIKN investor presentations & press releases · EIKN SEC filings · EIKN peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.